Login to View
StrategyR is a trade mark of Global Industry Analysts, Inc. USA
A trade mark of Global Industry Analysts, Inc.


Therapeutic Drug Monitoring

A Global Strategic Business Report

MCP22939


2    0
RESEARCH TRANSCRIPTS
Pharmacist Naloxone Education - NE Prescription Drug Monitoring Program (PDMP)
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

The Pharmacist Naloxone Education video will provide information specific to Nebraska’s expanded access legislation, naloxone standing order, and the pharmacist’s role in providing access to naloxone. If you wish to receive CE credit please return to http://dhhs.ne.gov/Pages/Drug-Overdose-Prevention-Naloxone.aspx and select the type of continued education credit you wish to receive.

TRANSCRIPT:

Alabama Prescription Drug Monitoring Program: Panel Discussion Q&A
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Description

TRANSCRIPT:

Prescription Drug Monitoring
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

TRANSCRIPT:

Alabama Prescription Drug Monitoring Program: Part 2
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Description

TRANSCRIPT:

Debate: Is therapeutic drug monitoring necessary with anti-TNF therapy? - No
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

In this presentation from the 2017 Great Debates and Updates in Inflammatory Bowel Disease, Dr. Bincy Abraham argues that therapeutic drug monitoring is not necessary when treating an IBD patient with anti-TNFs. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7248 © 2017 Imedex, LLC.

TRANSCRIPT:

AG Harris Praises Passage of Bill to Support Prescription Drug Monitoring
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Attorney General Kamala D. Harris is sponsoring legislation to upgrade and expand California's prescription drug monitoring program as an important step in combating a serious public health and law enforcement issue.

TRANSCRIPT:

The Effect of Prescription Drug Monitoring Programs on Opioid Detailing
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Center for Health Economics & Policy Studies November 29, 2018 David Bradford, University of Georgia

TRANSCRIPT:

Prescription Drug Monitoring and Opioid Prescribing Guidelines Panel
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Lastly is the panel discussion followed by a Q&A session. This panel explores how Indiana can help health care providers manage patients’ pain without fueling addition, with an emphasis on prescription drug monitoring programs, how they are used, and what potential they have. Panelists are Brad Ray, PhD, Dr. Jennifer Buehrle, and Dr. Christopher Suelzer. The panel is moderated by Sarah Fentem.

TRANSCRIPT:

Alabama Prescription Drug Monitoring Program: Part 1
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Description

TRANSCRIPT:

Prescription Drug Monitoring Program PDMP Training
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

The Nebraska Prescription Drug Monitoring Program (PDMP) Training video provides health care professionals with information about how to get registered to access the PDMP, how to view a patient’s medication history, what information is contained in the patient’s medication history, along with privacy and security restrictions. Individuals who qualify to access the Nebraska PDMP must complete the required PDMP training and training acknowledgement form to be granted access to the Nebraska PDMP. Here is the acknowledgement form link for the mandated training: https://www.surveymonkey.com/r/access... Additionally, 0.5 hours CME/CE will be available for prescribers (DO, MD) and pharmacists. For prescribers (DO, MD) go to the following link for the CME Assessment: https://nmaevents.wufoo.com/forms/xde... For pharmacists go to the following link for the CE Assessment: https://www.surveymonkey.com/r/PharmPDMP.

TRANSCRIPT:

Understanding the Prescription Drug Monitoring Program (PDMP) Mandate and Where You Fit In
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Prescription Drug Monitoring Program overview in our Summer Webinar Series Let us know what you think! Take this brief survey to tell us about your experience. https://www.surveymonkey.com/r/PDMPMandate?I=[I_value]&T=[T_value]

TRANSCRIPT:

The Art of Difficult Conversations - NE Prescription Drug Monitoring Program (PDMP)
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

The Pain Management Guidance Difficult Conversations education video provides in-depth information for health care professionals on tapering patients who are on opioids and/or benzodiazepines as outlined in the Nebraska Pain Management Guidance document. The education on the Nebraska Pain Management Guidance Document promotes consistent, safe, and effective pain management standards for Nebraska prescribers. It will assist in making clinical decisions easier, ensure patient safety and provide effective options to treat pain. http://dhhs.ne.gov/Pages/Drug-Overdose-Prevention-Pain-Management.aspx

TRANSCRIPT:

Prescription Drug Monitoring and Opioid Prescribing Guidelines, Jim McClelland
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Kicking off this event was Jim McClelland who serves as the Executive Director for Drug Prevention, Treatment, and Enforcement for the State of Indiana. This presentation focused on an overview of the opioid epidemic and its impact in Indiana. Mr. McClelland spoke about how Indiana is dealing with this complex problem by leveraging resources strategically to make a positive impact. He also touched on legislation and the state’s work in regards to prescription guidelines and Indiana’s prescription drug monitoring program INSPECT.

TRANSCRIPT:

Patients, Privacy, and PDMPs: Exploring the Impact of Prescription Drug Monitoring Programs
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Featuring David S. Fink, MPhil, MPH, Mailman School of Public Health, Columbia University; Kate M. Nicholson, JD, Civil rights attorney and pain patient advocate; Nathan Freed Wessler, JD, Staff attorney, ACLU Speech, Privacy, and Technology Project; Patience Moyo, PhD, Assistant Professor, Brown University School of Public Health; moderated by Jeffrey A. Singer, MD, Senior Fellow, Cato Institute. Prescription drug monitoring programs (PDMPs) operate in all 50 states and the District of Columbia. These statewide electronic databases of prescriptions dispensed for controlled substances were established in response to the opioid overdose crisis. Their purpose is to facilitate drug diversion investigations by law enforcement, change prescribing behavior, and reduce “doctor shopping” by patients who seek drugs for nonmedical use. In 28 states it is mandatory for providers to access the database and screen each time before prescribing any controlled substance to any patient. There is evidence that PDMPs have contributed to the dramatic 42 percent decline in prescription opioid volume since 2011. Many healthcare practitioners cite the inconvenience and workflow disruptions of mandatory-access PDMPs as deterrents to prescribing, while others fear scrutiny from law enforcement and licensing authorities — even for appropriate medical prescribing. This is unintentionally causing the undertreatment of patients with acute and chronic pain and, in some cases, the abrupt withdrawal of treatment from chronic pain patients. There is also evidence that PDMPs increase crime by driving nonmedical users from diverted prescription opioids to more harmful heroin and fentanyl, thus fueling overdoses. Finally, PDMPs pose a serious risk to medical privacy by allowing law enforcement to access confidential medical records without a warrant based on probable cause, which may be in violation of the Fourth Amendment. Learn more: https://www.cato.org/events/patients-privacy-and-pdmps Want to find the Cato Institute elsewhere on the internet? Facebook - https://www.facebook.com/CatoInstitute/ Twitter - https://twitter.com/CatoInstitute Instagram - https://www.instagram.com/CatoInstitute/ -

TRANSCRIPT:

Therapeutic Drug Monitoring: Nuts and Bolts
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Despite the existence of effective TB chemotherapy, challenges remain that often prevent high cure rates, especially in patients with concurrent illness. Slow response to TB therapy may lead to prolonged infectiousness or acquired drug resistance and further burdens public health by extending treatment duration. Therapeutic Drug Monitoring (TDM) is an effective tool which allows the clinician to make informed decisions regarding the timely adjustment of drug therapy especially for those patients who are slow to respond to treatment, have drug-resistant TB, are at risk of drug-drug interactions or have concurrent diseases. In this webinar the role and indications for use of Therapeutic Drug Monitoring in complex TB patients will be discussed. Presented by Charles Peloquin, Pharm.D., FCCP Reference article: Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA : http://wwwnc.cdc.gov/eid/article/16/10/10-0374_article.htm

TRANSCRIPT:

Therapeutic Drug Monitoring of Antibiotics
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Antibiotic resistance is becoming an ever-growing threat to healthcare delivery. Both the antibiotic misuse and insufficient dosing are the main reasons for resistance emergence. Given the lack of novel antibiotics under development, optimized drug exposure is essential to suppress the spread of antibiotic resistance. In the past therapeutic drug monitoring (TDM) has been employed only for antimicrobials with narrow therapeutic ranges, such as aminoglycosides. However, in recent years the knowledge about the altered pharmacokinetics in critically ill patients has led to a paradigm shift. Nowadays TDM of antibiotics is also advocated as a tool to guide dosage, ameliorating adequate drug exposure and therapeutic success in patients with severe infection, and at the same time minimizing the antimicrobial resistance. Accordingly, antibiotic TMD is becoming more widespread and increasingly recognized as a core element of hospital antibiotic stewardship programs. This webinar reviews the basal requirements, indications and practical aspects for rational antibiotic TDM in the intensive-care setting, with a special focus on the beta-lactams that are the most widely used antibiotic class. Quantification techniques and respective bottlenecks for affordable de-centralized testing are also discussed. Overview: Antimicrobial resistance: a threat to global health Pharmacokinetic/Pharmacodynamic (PK/PD) target attainment The paradigm shift of antibiotic therapeutic drug monitoring (TDM) Antibiotic stewardship (ABS): Rational antibiotic TDM in severe illness Quantification techniques Limited services for antibiotic TDM: future challenges

TRANSCRIPT:

Governor Wolf Lauds New Prescription Drug Monitoring Program
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Like Governor Tom Wolf on Facebook: www.facebook.com/governorwolf

TRANSCRIPT:

Therapeutic Drug Monitoring Past, Present, and Future
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

The practice of beta-lactam therapeutic drug monitoring in pediatrics is a relatively new and cutting edge. This presentation will describe the need and role for this potentially valuable intervention. Attendees of this session will be able to: 1. Review background information regarding therapeutic drug monitoring (TDM) 2. Discuss the evidence behind beta-lactam TDM 3. Illustrate opportunities to utilize beta-lactam TDM 10 10 2018

TRANSCRIPT:

Beckman Coulter at Medlab Middle East 2023
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

TRANSCRIPT:

#LiveWithChaudhrey with Paul Royle Bio-Rad Laboratories at #PEGSEurope2021 Day 2 Nov 3rd
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

It was great to catch up with Paul and learn about their products and platforms that shorten discovery and development timeline for #noveltherapeutics, #biosimilars, and #cellandgenetherapies. Paul's colleague, Francisco Ylera, presented at the conference on "CAR-T Cell Analysis with Modular Antibodies using SpyTag Protein Ligation", and it is now available to view on demand on the event app. Visit www.biorad.com for more info

TRANSCRIPT:

2    0